Literature DB >> 21679677

Genetic characterisation of the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010.

S Thulin Hedberg1, B Törös, H Fredlund, P Olcén, P Mölling.   

Abstract

Neisseria meningitidis serogroups B and C have been responsible for the majority of invasive meningococcal disease in Europe. Recently, an increase of N. meningitidis disease due to serogroup Y has been noted in Sweden (in 2010, the proportion was 39%, with an incidence of 0.23 per 100,000 population), as well as in other northern European countries. We aimed to investigate the clonal pattern of the emerging serogroup Y in Sweden during 2000 to 2010. The serogroup Y isolates identified during this time (n=85) were characterised by multilocus sequence typing and sequencing of the fetA, fHbp, penA, porA and porB genes. The most frequent clone (comprising 28 isolates) with identical allele combinations of the investigated genes, was partly responsible for the observed increased number of N. meningitidis serogroup Y isolates. It was sulfadiazine resistant, with genosubtype P1.5-2,10-1,36-2, sequence type 23, clonal complex 23, porB allele 3-36, fetA allele F4-1, fHbp allele 25 and penA allele 22. The first case with disease due to this clone was identified in 2002: there was a further case in 2004, six during 2006 to 2007, eight during 2008 to 2009, with a peak of 12 cases in 2010. An unusual increase of invasive disease in young adults (aged 20–29 years) caused by this clone was shown, but no increase in mortality rate was observed.

Entities:  

Mesh:

Year:  2011        PMID: 21679677

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  19 in total

1.  Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland.

Authors:  Ulla Jounio; Annika Saukkoriipi; Holly B Bratcher; Aini Bloigu; Raija Juvonen; Sylvi Silvennoinen-Kassinen; Ari Peitso; Terttu Harju; Olli Vainio; Markku Kuusi; Martin C J Maiden; Maija Leinonen; Helena Käyhty; Maija Toropainen
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

2.  Genomic Analysis of Serogroup Y Neisseria meningitidis Isolates Reveals Extensive Similarities Between Carriage-Associated and Disease-Associated Organisms.

Authors:  Neil J Oldfield; Odile B Harrison; Christopher D Bayliss; Martin C J Maiden; Dlawer A A Ala'Aldeen; David P J Turner
Journal:  J Infect Dis       Date:  2016-01-07       Impact factor: 5.226

3.  Genome-Based Characterization of Emergent Invasive Neisseria meningitidis Serogroup Y Isolates in Sweden from 1995 to 2012.

Authors:  Bianca Törös; Sara T Hedberg; Magnus Unemo; Susanne Jacobsson; Dorothea M C Hill; Per Olcén; Hans Fredlund; Holly B Bratcher; Keith A Jolley; Martin C J Maiden; Paula Mölling
Journal:  J Clin Microbiol       Date:  2015-04-29       Impact factor: 5.948

4.  Bacteraemic pneumonia caused by Neisseria meningitidis serogroup Y.

Authors:  Maria Pilar Romero-Gomez; Zaida Rentero; Jose Ramon Paño; Jesus Mingorance
Journal:  Respir Med Case Rep       Date:  2011-12-26

5.  Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.

Authors:  Paul A Kristiansen; Absatou Ky Ba; Abdoul-Salam Ouédraogo; Idrissa Sanou; Rasmata Ouédraogo; Lassana Sangaré; Fabien Diomandé; Denis Kandolo; Inger Marie Saga; Lara Misegades; Thomas A Clark; Marie-Pierre Préziosi; Dominique A Caugant
Journal:  BMC Infect Dis       Date:  2014-12-04       Impact factor: 3.090

6.  A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.

Authors:  Timo Vesikari; Aino Forstén; Dominique Boutriau; Véronique Bianco; Marie Van der Wielen; Jacqueline M Miller
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

7.  Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

Authors:  Markus Knuf; Olivier Romain; Klaus Kindler; Uta Walther; Phu-My Tran; Heidemarie Pankow-Culot; Thomas Fischbach; Dorothee Kieninger-Baum; Véronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Eur J Pediatr       Date:  2013-01-11       Impact factor: 3.183

8.  Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.

Authors:  Timo Vesikari; Aino Forstén; Dominique Boutriau; Véronique Bianco; Marie Van der Wielen; Jacqueline M Miller
Journal:  Hum Vaccin Immunother       Date:  2012-10-02       Impact factor: 3.452

9.  Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development.

Authors:  Carina Brehony; Caroline L Trotter; Mary E Ramsay; Manosree Chandra; Keith A Jolley; Arie van der Ende; Françoise Carion; Lene Berthelsen; Steen Hoffmann; Hjördís Harðardóttir; Julio A Vazquez; Karen Murphy; Maija Toropainen; Manuela Caniça; Eugenia Ferreira; Mathew Diggle; Giles F Edwards; Muhamed-Kheir Taha; Paola Stefanelli; Paula Kriz; Steve J Gray; Andrew J Fox; Susanne Jacobsson; Heike Claus; Ulrich Vogel; Georgina Tzanakaki; Sigrid Heuberger; Dominique A Caugant; Matthias Frosch; Martin C J Maiden
Journal:  Clin Vaccine Immunol       Date:  2014-04-02

10.  Increase of Neisseria meningitidis W:cc11 invasive disease in Chile has no correlation with carriage in adolescents.

Authors:  Paulina S Rubilar; Gisselle N Barra; Jean-Marc Gabastou; Pedro Alarcón; Pamela Araya; Juan C Hormazábal; Jorge Fernandez
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.